Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004874 · ClinicalTrials.gov registry record · Phase 3
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT00004874: Clinical Trial Phase 3 study, sponsored by University of Nebraska.
NCT00004874 is a Phase 3 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 31 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004874, a Phase 3 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Primary Outcome
The primary objective of this stud is to make Iodin-131 Anti-B1 Antibody more broadly available to patients
Interventions
- RADIATION tositumomab and iodine I 131 tositumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 1998-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Why NCT00004874 stopped before completion
NCT00004874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which tositumomab and iodine I 131 tositumomab is the first listed.
NCT00004874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004874 about?
NCT00004874 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Ho...
What is the current status of trial NCT00004874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 1998-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00004874?
The interventions under investigation include: tositumomab and iodine I 131 tositumomab (RADIATION).
Who is sponsoring clinical trial NCT00004874?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004874's enrollment target sits among peer trials
31 1914th of 2000 higher than 84 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia